Singulair-induced anaphylaxis?

Journal of Family Practice

Volumn 58, Issue 3, 2009, Pages 133-134

  Gerard, Adriel ^a   Harkisoon, Shantie ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b St Dominic's Health Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; DIPHENHYDRAMINE; MONTELUKAST; SALBUTAMOL;

ALLERGIC CONJUNCTIVITIS; ANAPHYLAXIS; ASTHMA; ATOPY; CASE REPORT; CHILD; DRUG HYPERSENSITIVITY; FACE EDEMA; FOOT EDEMA; HUMAN; MALE; PRESCHOOL CHILD; PRURITUS; SHORT SURVEY; URTICARIA;

ACETATES; ANAPHYLAXIS; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD, PRESCHOOL; CONJUNCTIVITIS, ALLERGIC; DERMATITIS, ATOPIC; HUMANS; INFANT; LEUKOTRIENE ANTAGONISTS; MALE; PROGNOSIS; QUINOLINES; RESPIRATORY HYPERSENSITIVITY;

EID: 61849185920     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (4)

1. Singulair (montelukast sodium) [prescribing information]. Whitehouse Station, NJ: Merck & Co., Inc; 2008.
2. Biswas P, Wilton L, Pearce G, et al. Pharmacosurveillance and safety of the leukotriene receptor antagonist (LTRA), montelukast. Clin Exp All Rev. 2001;3:300-304.
3. Millikan E. XML drug information modeling: linking evidence-based medicine with the bedside. In Proceedings of Health Information Management Systems Society. February 13-17, 2005. Available at: www.himss.org/content/ files/2005proceedings/sessions/edu031.pdf. Accessed February 2, 2009.
4. An overview of reports on montelukast. Available at: www.lareb.nl/ documents/kwb-2002-3-monte.pdf. Accessed February 2, 2009.